Assenagon Asset Management S.A. Sells 5,956 Shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

Assenagon Asset Management S.A. decreased its position in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) by 3.6% during the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 161,399 shares of the company’s stock after selling 5,956 shares during the quarter. Assenagon Asset Management S.A. owned approximately 0.34% of Amphastar Pharmaceuticals worth $5,993,000 at the end of the most recent quarter.

Several other large investors have also made changes to their positions in AMPH. GAMMA Investing LLC increased its stake in Amphastar Pharmaceuticals by 70.0% in the 3rd quarter. GAMMA Investing LLC now owns 663 shares of the company’s stock worth $32,000 after acquiring an additional 273 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. raised its holdings in Amphastar Pharmaceuticals by 53.4% during the 3rd quarter. Point72 Asia Singapore Pte. Ltd. now owns 1,144 shares of the company’s stock valued at $56,000 after buying an additional 398 shares during the period. Asset Management One Co. Ltd. purchased a new position in Amphastar Pharmaceuticals during the third quarter worth $78,000. Mirae Asset Global Investments Co. Ltd. increased its position in Amphastar Pharmaceuticals by 20.6% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,761 shares of the company’s stock valued at $85,000 after acquiring an additional 301 shares during the last quarter. Finally, nVerses Capital LLC lifted its holdings in shares of Amphastar Pharmaceuticals by 18.2% in the 3rd quarter. nVerses Capital LLC now owns 2,600 shares of the company’s stock worth $126,000 after acquiring an additional 400 shares during the last quarter. 65.09% of the stock is currently owned by hedge funds and other institutional investors.

Amphastar Pharmaceuticals Trading Up 0.1 %

Shares of NASDAQ:AMPH opened at $35.70 on Monday. The company has a market capitalization of $1.72 billion, a PE ratio of 11.90, a P/E/G ratio of 1.12 and a beta of 0.82. The company has a current ratio of 3.43, a quick ratio of 2.61 and a debt-to-equity ratio of 0.82. Amphastar Pharmaceuticals, Inc. has a 12-month low of $34.60 and a 12-month high of $56.88. The business’s fifty day simple moving average is $41.15 and its 200-day simple moving average is $44.12.

Insider Buying and Selling

In other Amphastar Pharmaceuticals news, EVP Rong Zhou sold 7,000 shares of the firm’s stock in a transaction that occurred on Thursday, December 12th. The shares were sold at an average price of $44.42, for a total transaction of $310,940.00. Following the completion of the transaction, the executive vice president now directly owns 118,469 shares of the company’s stock, valued at approximately $5,262,392.98. This trade represents a 5.58 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, CFO William J. Peters sold 7,426 shares of the company’s stock in a transaction on Wednesday, November 6th. The shares were sold at an average price of $52.05, for a total transaction of $386,523.30. Following the completion of the sale, the chief financial officer now directly owns 94,103 shares in the company, valued at approximately $4,898,061.15. The trade was a 7.31 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 41,533 shares of company stock worth $1,987,482 in the last three months. Corporate insiders own 27.10% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on the company. Wells Fargo & Company initiated coverage on Amphastar Pharmaceuticals in a report on Friday, November 22nd. They issued an “equal weight” rating and a $55.00 price target on the stock. StockNews.com cut shares of Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, November 1st. Three analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to data from MarketBeat.com, Amphastar Pharmaceuticals presently has an average rating of “Hold” and an average target price of $60.33.

Amphastar Pharmaceuticals Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.